ArmaGen is a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Our lead product candidates, AGT-182 for Hunter syndrome and AGT-181 for Hurler syndrome, are both funded. AGT-182 is currently in Phase 1 clinical trials, and AGT-181 is in Phase 2 clinical trials.
ArmaGen closed a $17 million series A financing in 2012 led by a consortium of top biopharmaceutical investment firms. The investor group is led by the Boehringer Ingelheim Venture Fund GmbH, and includes Shire plc, Takeda Ventures, Inc. and Mitsui Corporation Venture Partnership Technology Fund I, LLC.
Key opinion leaders provide their perspectives on recently presented AGT-181 data, what these data mean for Hurler patients and the implications of these data on other lysosomal storage diseases and central nervous system disorders.